NCT06146764 CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
| NCT ID | NCT06146764 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Condition | Thyroid Nodule |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2023-03-18 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2023-03-18 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Contrast-enhanced ultrasound (CEUS) can sensitively show the blood perfusion characteristics of thyroid nodules, which is a useful supplement to gray-scale ultrasound. However, there is no standard combined diagnostic method of gray-scale ultrasound and CEUS. Therefore, the aim of this study was to compare the diagnostic performance of the integrated scoring method and the up-and-down scoring method. This study was a multicenter retrospective clinical study and followed the Standards for Reporting of Diagnostic Accuracy Studies (version 2015). Inclusion criteria: 1) participants with at least one thyroid nodule larger than 5 mm confirmed by conventional ultrasound; 2) participants underwent gray-scale ultrasound, contrast-enhanced ultrasound and fine needle aspiration biopsy of the thyroid nodule successively; 3) participants have a final diagnosis of benign or malignant. Exclusion criteria included: 1) participants with cytologic findings of Bethesda I, III, or IV without definitive benign or malignant pathologic findings; 2) participants with a history of thyroid fine needle aspiration, ablation or surgery; 3) participants with low quality ultrasound images (e.g., severe artifacts or low image resolution). According to the American College of Radiology Thyroid Imaging Reporting and Data System, only one thyroid nodule with the highest point was included in each participant. A total of 600 participants from January 2018 to December 2022 were consecutively included in Sun Yat-sen Memorial Hospital of Sun Yat-sen University to form a training set (average age 48 years; Range 24-81 years old). A total of 200 subjects with thyroid nodules from January 2022 to December 2022 were consecutively included to form an external validation set in Houjie Hospital of Dongguan City, Guangdong Province (mean age 46 years; Range 30-74 years). The malignant risk of enrolled thyroid nodules and the necessity of biopsy were evaluated by integrated scoring method and up-and-down scoring method, respectively. The diagnostic performance and unnecessary biopsy rate of the above two methods were calculated and compared.
Eligibility Criteria
Inclusion Criteria: * Participants with thyroid nodules with a solid component ≥5 mm confirmed by conventional ultrasound; * Participants who underwent conventional ultrasound, contrast-enhanced ultrasound, and fine-needle aspiration biopsy; * Participants with a final benign or malignant pathological results. Exclusion Criteria: * Participants with cytopathology of Bethesda I, III, or IV and without final benign or malignant pathology； * Participants with a history of thyroid ablation or surgery; * Participants with low-quality ultrasound images.
Contact & Investigator
Jingliang Ruan, Ph.D.
PRINCIPAL INVESTIGATOR
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Frequently Asked Questions
Who can join the NCT06146764 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Nodule. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06146764 currently recruiting?
Yes, NCT06146764 is actively recruiting participants. Contact the research team at ruanjl3@mail.sysu.edu.cn for enrollment information.
Where is the NCT06146764 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06146764 clinical trial?
NCT06146764 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The principal investigator is Jingliang Ruan, Ph.D. at Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The trial plans to enroll 800 participants.